Publications by authors named "J Romero Lombard"
Concepts in Understanding Infectious Disease Dynamics in Populations.
Vet Clin North Am Food Anim Pract
January 2025
Veterinarians are better prepared to assist producers in disease prevention, control, and eradication when they understand the relationships among the agent, the host, and the environment. Although vaccination may reduce disease prevalence in a herd, test and selective removal remain the most common method of disease control.
View Article and Find Full Text PDFBiosecurity Practices for Mycobacterium aviun subspecies paratuberculosis Infection, Salmonellosis, and Bovine Leukemia Virus on Cattle Operations.
Vet Clin North Am Food Anim Pract
December 2024
Mycobacterium avium subspecies paratuberculosis infection, salmonellosis, and bovine leukosis virus are important dairy and beef cattle diseases from a health perspective. For herds without infection, keeping the disease out through testing of source herds should be prioritized. For herds with infection, control programs should be instituted and followed to reduce the prevalence and ultimately eliminate the disease.
View Article and Find Full Text PDFAim: Do Not Attempt Cardiopulmonary Resuscitation (DNACPR) codes record the decision to withhold CPR in cases of circulatory arrest. These decisions involve various clinical, ethical and legal complexities promoting increased focus on the decision-making process. This research sought to capture healthcare workers perspective on DNACPR practices and policies in Ireland.
View Article and Find Full Text PDFArticle Synopsis
- Imlunestrant is a next-generation oral selective estrogen receptor degrader being tested in the EMBER trial for patients with ER+ advanced breast cancer and endometrioid endometrial cancer (EEC).
- The trial involves a dose-escalation design to determine optimal doses and measure safety, pharmacokinetics, and anticancer effects, focusing specifically on patients who have already undergone certain previous treatments.
- Results showed manageable side effects and some evidence of antitumor activity, with better outcomes observed when imlunestrant was combined with abemaciclib compared to imlunestrant alone.
Background: Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer. Here we present the final 10-year analysis of the ALTTO trial.
Patients And Methods: The ALTTO trial (NCT00490139) is a prospective randomized, phase III, open-label, multicenter study that investigated the role of adjuvant chemotherapy and trastuzumab alone, in combination or sequentially with lapatinib.